These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
979 related articles for article (PubMed ID: 21209520)
1. Multi-drug resistant tuberculosis burden and risk factors: an update. Marahatta SB Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520 [TBL] [Abstract][Full Text] [Related]
2. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Yew WW Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001 [TBL] [Abstract][Full Text] [Related]
3. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336 [TBL] [Abstract][Full Text] [Related]
4. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266 [TBL] [Abstract][Full Text] [Related]
5. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Multidrug-resistant Tuberculosis. Rumende CM Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169 [TBL] [Abstract][Full Text] [Related]
7. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118 [TBL] [Abstract][Full Text] [Related]
8. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Chang KC; Yew WW Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408 [TBL] [Abstract][Full Text] [Related]
9. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117 [TBL] [Abstract][Full Text] [Related]
10. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848 [TBL] [Abstract][Full Text] [Related]
11. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead. van Maaren PJ Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671 [TBL] [Abstract][Full Text] [Related]
12. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study. Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of treating multidrug-resistant tuberculosis. Resch SC; Salomon JA; Murray M; Weinstein MC PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403 [TBL] [Abstract][Full Text] [Related]
14. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Ahmad S; Mokaddas E Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927 [TBL] [Abstract][Full Text] [Related]
17. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases. Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008 [TBL] [Abstract][Full Text] [Related]
19. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Kendall EA; Cohen T; Mitnick CD; Dowdy DW Int J Infect Dis; 2017 Mar; 56():185-189. PubMed ID: 28007660 [TBL] [Abstract][Full Text] [Related]
20. Isoniazid mono-resistant tuberculosis: Time to take it seriously. Garg K; Saini V; Dhillon R; Agarwal P Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]